Why Are Antibiotics Bad for You? The Real Risks

Antibiotics save lives, but they are not free of consequences. Every course of antibiotics disrupts the community of microbes living in your gut, and that disruption ripples outward in ways researchers are still cataloging: heightened susceptibility to certain infections, increased risk of inflammatory bowel disease, potential effects on mood and metabolism, and direct toxicity to organs and tissues from specific drug classes. The risks scale with how often you take antibiotics, which ones you take, and when in life you take them, and the science on these harms has grown considerably in recent years.

What Happens to Your Gut Microbiome

The most universal harm from antibiotics is collateral damage to the trillions of bacteria that normally inhabit your intestines. Antibiotics cannot distinguish between the bacteria causing your infection and the beneficial ones keeping your gut healthy. The result is reduced microbial diversity, loss of key bacterial families, and shifts in the metabolic output of whatever community remains.¹ Broad-spectrum antibiotics hit particularly hard: in hospitalized patients receiving them, researchers found significantly lower gut diversity and a depletion of bacterial species known to produce short-chain fatty acids, which are compounds your colon cells rely on for energy and immune signaling.²

This is not just an abstract ecological shift. When the bacterial landscape changes, the chemical environment of your gut changes with it. Bile acids that your normal gut flora would convert into protective secondary forms go unconverted. Metabolic byproducts that feed your intestinal lining disappear. And the empty niches left behind become open real estate for organisms you do not want moving in.

Opportunistic Infections After Antibiotic Use

The most dangerous squatter is Clostridioides difficile, a bacterium that causes severe diarrhea, colon inflammation, and in serious cases, life-threatening complications. Normally, the secondary bile acids produced by healthy gut bacteria suppress C. difficile spore germination. Broad-spectrum antibiotics like cefoperazone, clindamycin, and vancomycin wipe out the bacterial families responsible for making those bile acids, and once secondary bile acid levels drop, C. difficile spores can germinate and take hold in the large intestine.³

Vaginal yeast infections are another common consequence, particularly for women taking broad-spectrum antibiotics. The mechanism is parallel: antibiotics reduce or alter the vaginal microbiome’s ability to keep Candida species in check, allowing yeast to proliferate and express traits that cause symptoms.⁴ These infections are typically treatable, but they illustrate a broader principle: antibiotics do not just fight one pathogen, they reshape the entire microbial environment, and when that environment shifts, opportunistic organisms fill the gap.

Antibiotics and Inflammatory Bowel Disease

One of the more concerning long-term associations is between antibiotic use and the development of inflammatory bowel disease. A systematic review and meta-analysis found that antibiotic exposure was linked to a roughly 40 percent higher risk of new-onset IBD, with a clear dose-response pattern: the more prescriptions, the higher the risk.⁵ A large population-based cohort study found the association held across all age groups but was strongest in people over 40, and a positive dose-response was observed for both ulcerative colitis and Crohn’s disease.⁶

A Scandinavian case-control study put the numbers even higher: compared with people who had never used antibiotics, those with any antibiotic use had nearly double the odds of being diagnosed with IBD, with Crohn’s disease showing the steeper increase. The risk climbed with each additional dispensation and was particularly elevated for broad-spectrum agents. Even when the researchers used siblings as a comparison group to control for shared genetics and upbringing, the association persisted, though it was somewhat smaller.⁷

These are observational findings, and there is an important caveat: people who later develop IBD may visit the doctor more and receive more antibiotics in the years before diagnosis, simply because they have early, unrecognized symptoms. Researchers try to account for this with lag periods and sibling comparisons, and the dose-response pattern strengthens the case for a real biological effect. Still, this is an area where correlation is strong but causation remains debated.

Risks for Children

Children’s developing microbiomes appear to be especially vulnerable to antibiotic disruption. The clearest association is with asthma. An early study found that antibiotic use during the first year of life roughly doubled the odds of developing hay fever and raised asthma risk by about 70 percent.⁸ More recent work has reinforced this, finding a dose-dependent relationship: in children with atopic dermatitis, antibiotic exposure was tied to more than a threefold increase in new-onset asthma, with the strongest effect in children under five.⁹

A twin study helps address the obvious concern that sicker children simply get more antibiotics and more asthma diagnoses. In unmatched analyses across two large twin registries, early-life antibiotics were associated with a 30 to 45 percent increase in asthma risk. However, when the researchers compared twins within a pair, where both children share genetics and household environment, the association weakened or disappeared, suggesting that confounding by shared family factors explains at least some of the link.¹⁰ So the relationship between childhood antibiotics and asthma is real at the population level, but how much is caused by antibiotics versus by the infections that prompted them remains genuinely uncertain.

Childhood obesity is another area of concern. Agents that disrupt microbiome composition early in life can affect body mass, either promoting weight gain or, in malnourished populations, stunting growth.¹¹ The proposed mechanism involves changes to the metabolic activity of the gut flora, which in turn alters how the body extracts and stores energy from food. Some researchers have begun exploring whether adding specific probiotics during pediatric antibiotic courses could offset this risk.¹²

Direct Organ and Tissue Toxicity

Beyond microbiome-mediated effects, certain antibiotic classes cause direct damage to specific organs. These are not subtle statistical associations but well-documented pharmacological toxicities that doctors weigh every time they prescribe these drugs.

Fluoroquinolones, a class that includes ciprofloxacin and levofloxacin, carry a well-known risk of tendon damage and rupture. Lab studies suggest these drugs are directly toxic to tendon cells through several pathways, including generation of reactive oxygen species that cause oxidative stress and activation of enzymes that degrade the tendon’s structural matrix.¹³ The Achilles tendon is the most commonly affected, and the risk is higher in older adults and people taking corticosteroids. The FDA has added increasingly severe warnings to fluoroquinolone labels over the years.

Aminoglycosides, used for serious gram-negative infections, can damage the kidneys and cause irreversible hearing loss. The ototoxicity occurs because the drug passes freely into the hair cells of the inner ear and generates reactive oxygen species that destroy mitochondria, leading to cell death. Kidney damage happens through a different route: the drug accumulates in the cells of the kidney’s proximal tubules and disrupts lysosomal function.¹⁴ In pediatric patients, the ototoxicity is a particular concern because permanent hearing loss early in life affects language development.¹⁵

Liver injury is associated with several antibiotics, but amoxicillin-clavulanate (the combination sold as Augmentin) is one of the most common culprits. In a large drug-induced liver injury registry, amoxicillin-clavulanate accounted for about 11 percent of all cases and nearly a quarter of those caused by antimicrobials. Symptoms typically appeared about a month into treatment, and liver biopsies consistently showed prominent cholestatic features. Most patients recovered, with liver markers normalizing about two months after the peak, though a small number required liver transplantation.¹⁶

Mitochondrial Damage in Your Own Cells

A less widely known risk involves antibiotics damaging the energy-producing machinery inside your own cells. Mitochondria evolved from ancient bacteria and share structural features with modern bacteria, which means antibiotics designed to attack bacterial processes sometimes hit mitochondria too. Research has shown that clinically relevant doses of bactericidal antibiotics (quinolones, aminoglycosides, and beta-lactams) cause mitochondrial dysfunction and an overproduction of reactive oxygen species in mammalian cells. This oxidative burst leads to damage to DNA, proteins, and cell membranes.¹⁷ The clinical significance of this is still being worked out, but it provides a plausible biological explanation for some of the fatigue and malaise people report during and after antibiotic courses.

Heart Rhythm Disturbances

Macrolide antibiotics like azithromycin and erythromycin, along with some fluoroquinolones, can interfere with the electrical activity of the heart. These drugs block a specific potassium channel in heart muscle cells, which prolongs the interval between heartbeats and can trigger dangerous arrhythmias.¹⁸ The FDA strengthened warning labels on azithromycin after observational evidence linked macrolides to torsade de pointes and other ventricular arrhythmias.¹⁹ A Taiwanese population-level study found that azithromycin and moxifloxacin were associated with significantly increased risks of ventricular arrhythmia and cardiovascular death compared with amoxicillin-clavulanate.²⁰ The absolute risk for any individual course remains low, but it matters for people who already have heart conditions or who take other medications that prolong the QT interval.

Severe Allergic Reactions

Most antibiotic allergies produce mild symptoms like rash or hives. Rarely, antibiotics trigger Stevens-Johnson syndrome or toxic epidermal necrolysis, severe conditions where the skin blisters and peels off, requiring intensive care. A meta-analysis of 38 studies covering nearly 3,000 patients with these conditions found that antibiotics accounted for about 28 percent of all cases. Among antibiotic-triggered cases, sulfonamides were responsible for roughly a third, penicillins for about a fifth, and cephalosporins for about a tenth.²¹ These reactions are rare enough that most people will never encounter them, but they are a reminder that antibiotics carry serious tail risks beyond the common side effects.

How Antibiotics Breed Resistance Inside You

When you take antibiotics, you do not just kill susceptible bacteria; you also select for resistant ones and give them room to multiply. Research has found that even a short course of antibiotics increases the average copy number of resistance genes in your gut, diversifies the types of resistance genes present, and more than 30 percent of those genes undergo rapid genetic changes at the single-nucleotide level during treatment. The potential for horizontal gene transfer, where resistance genes jump between bacterial species, increased roughly threefold among the genes undergoing the most change.²²

Even in a controlled trial where healthy men received a short cocktail of last-resort antibiotics, researchers observed a clear shift in the gut’s resistance gene profile within days of finishing treatment. The shift persisted at six weeks and did not fully resolve until about six months later.²³ This means that for months after an antibiotic course, your gut flora carries an elevated load of resistance genes that could potentially be shared with incoming pathogens.

How Long Recovery Takes

A question people rarely ask their doctor is how long their microbiome takes to bounce back. The honest answer: longer than most expect, and possibly never completely. A study tracking recovery after common outpatient antibiotics found that species richness returned to pre-treatment levels after about two months in most people, but the composition of the community, its resistance gene profile, and its metabolic output remained altered. Azithromycin delayed recovery further.²⁴

Repeated courses compound the problem. A study giving subjects two courses of ciprofloxacin several months apart found that while communities began returning toward their initial state within a week of each course ending, the return was often incomplete. By the end of the observation period, every subject’s microbiome had stabilized, but at a new baseline that differed from where it started.²⁵ The recovery pattern was also highly individual: two people taking the same drug at the same dose experienced different community shifts and different degrees of return.

The Gut-Brain Connection

Your gut microbiome communicates with your brain through several pathways, including the vagus nerve and the production of metabolites that influence neurotransmitter synthesis. When antibiotics disrupt the microbiome, these signaling channels can be affected. Gut bacteria help regulate tryptophan, the amino acid your body uses to make serotonin, and some antibiotics significantly reduce the diversity of the microbial communities involved in this process. Researchers have flagged this as a potential risk factor for depression and anxiety, alongside other antibiotic-induced changes like altered gut barrier function and reduced levels of brain-derived neurotrophic factor.²⁶

Animal studies have provided more direct evidence: mice given oral antibiotics developed increased anxiety, depressive-like behaviors, impaired spatial memory, and heightened pain sensitivity. Administering probiotics partially reversed these behavioral changes.²⁷ The relevance to humans is still being established, and translating mouse behavior studies to human mental health requires caution. But it is increasingly clear that the consequences of antibiotic-induced gut disruption extend well beyond the digestive system.

Antibiotics and Cancer Treatment

One of the more surprising findings in recent years involves antibiotics undermining cancer immunotherapy. Immune checkpoint inhibitors, drugs that help the immune system attack tumors, appear to work partly through the gut microbiome. In a study of nearly 300 patients with advanced cancer, those who received multiple or prolonged courses of antibiotics during treatment had dramatically worse outcomes: their median overall survival was about six months, compared with nearly 22 months for patients who did not need antibiotics. The effect was independent of other clinical factors.²⁸ This does not mean cancer patients should refuse antibiotics when they have infections, but oncologists are increasingly aware that antibiotic stewardship may affect immunotherapy outcomes.

Antibiotics Given to Mothers During Delivery

Antibiotics administered to mothers before or during delivery, most commonly to prevent Group B Streptococcus transmission, consistently alter the microbiome their newborns acquire. Exposed infants show decreased diversity and a characteristic shift: fewer Bacteroidetes and Bifidobacteria, more Proteobacteria.²⁹ These effects were most pronounced in babies born vaginally, which makes sense because vaginal delivery is the primary route by which a newborn is first colonized by its mother’s microbes.³⁰ The long-term health implications of this altered early colonization are an active area of research, with some investigators linking it to the pediatric risks discussed earlier.

Low-Dose Exposure Through Food

You do not have to take a prescription to be exposed to antibiotics. Trace amounts from agricultural use can reach consumers through food, and even at very low doses, the effects on gut microbiota may not be trivial. In mice, exposure to antibiotic residues at levels representing theoretical maximal daily intake from food facilitated high-fat-diet-induced obesity and insulin resistance. When the researchers transplanted gut microbes from the exposed mice into germ-free animals, the obesity-related traits transferred along with them, confirming that the effect was driven by changes in the microbiome rather than a direct metabolic action of the drug.³¹ Whether typical real-world dietary exposures in humans have the same effect is not yet proven, but this line of research adds urgency to debates about antibiotic use in agriculture.

Why Narrow-Spectrum Antibiotics Matter

Not all antibiotics cause the same degree of collateral damage. How much harm an antibiotic does to your microbiome depends on its spectrum of activity, the dose, the duration, and the route of administration.³² Broad-spectrum agents, by definition, kill a wider range of bacteria and tend to cause more disruption. In a laboratory model of the human colon, researchers compared broad-spectrum antibiotics with a narrow-spectrum bacteriocin called thuricin CD, which targeted em>C. difficile specifically. All the broad-spectrum drugs shifted gut community composition substantially, reducing Firmicutes and Bacteroidetes while Proteobacteria surged. The narrow-spectrum agent killed C. difficile just as effectively but left the rest of the microbial community largely intact.³³

This is the practical takeaway behind antibiotic stewardship programs. When your doctor takes the time to identify the specific bacterium causing your infection and prescribes a narrow-spectrum antibiotic that targets it, you get the same therapeutic benefit with substantially less friendly-fire damage to the rest of your microbial ecosystem. Asking whether a narrower antibiotic is an option is a reasonable conversation to have, especially if you have risk factors for the downstream consequences discussed throughout this article.